Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...
In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.
Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...
Eli Lilly & Co. is tapping the U.S. investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase ...
Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...
Diversity was a loaded term for the participants of a Black History Month panel held by the city of Frederick on Monday. “The pain of diversity [is] when no matter what position I am put in ...
The company said it could hire around a dozen people if helmet sales are strong. STORY HIGHLIGHTS STX shifts helmet manufacturing to Baltimore after seven-figure investment. Aero helmets to be ...
On top of that, Eli Lilly has a number of exciting oncology drugs in the works, including STX-478 from Scorpion Therapeutics, for which the company recently paid $2.5 billion. All of this is to ...
Meanwhile, Eli Lilly announced plans to acquire Scorpion Therapeutics’ STX-478, a P13K inhibitor which is in phase I trials for breast cancer and other advanced solid tumours. GSK flagged the US ...